WO1994015958A3 - Inhibiteurs peptidiques de l'adhesion cellulaire - Google Patents

Inhibiteurs peptidiques de l'adhesion cellulaire Download PDF

Info

Publication number
WO1994015958A3
WO1994015958A3 PCT/IB1994/000026 IB9400026W WO9415958A3 WO 1994015958 A3 WO1994015958 A3 WO 1994015958A3 IB 9400026 W IB9400026 W IB 9400026W WO 9415958 A3 WO9415958 A3 WO 9415958A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell adhesion
peptide inhibitors
adhesion
disclosed
cyclized
Prior art date
Application number
PCT/IB1994/000026
Other languages
English (en)
Other versions
WO1994015958A2 (fr
Inventor
Shiu-Lang Ng Chiang
Pina M Cardarelli
Thomas J Lobl
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Priority to JP6516421A priority Critical patent/JPH08505628A/ja
Priority to EP94906984A priority patent/EP0677060A1/fr
Priority to KR1019950702798A priority patent/KR960700270A/ko
Publication of WO1994015958A2 publication Critical patent/WO1994015958A2/fr
Publication of WO1994015958A3 publication Critical patent/WO1994015958A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Antagonistes de récepteurs d'intégrine cyclisés utilisables pour moduler l'adhésion cellulaire, notamment l'adhésion associée à la fibronectine, ainsi que l'adhésion des leucocytes aux cellules endothéliales. On a également prévu des procédés de synthèse, de test, de formulation et d'utilisation desdits composés comme agents thérapeutiques.
PCT/IB1994/000026 1993-01-08 1994-01-07 Inhibiteurs peptidiques de l'adhesion cellulaire WO1994015958A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP6516421A JPH08505628A (ja) 1993-01-08 1994-01-07 ペプチド型細胞接着阻害薬
EP94906984A EP0677060A1 (fr) 1993-01-08 1994-01-07 Inhibiteurs peptidiques de l'adhesion cellulaire
KR1019950702798A KR960700270A (ko) 1993-01-08 1994-01-07 세포 유착에 대한 펩타이드 억제제(peptide inhibitors of cell adhesion)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US177393A 1993-01-08 1993-01-08
US08/001,773 1993-01-08
CN94115995A CN1114961A (zh) 1993-01-08 1994-07-11 细胞粘连肽抑制剂

Publications (2)

Publication Number Publication Date
WO1994015958A2 WO1994015958A2 (fr) 1994-07-21
WO1994015958A3 true WO1994015958A3 (fr) 1994-09-29

Family

ID=37075853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1994/000026 WO1994015958A2 (fr) 1993-01-08 1994-01-07 Inhibiteurs peptidiques de l'adhesion cellulaire

Country Status (6)

Country Link
EP (1) EP0677060A1 (fr)
JP (1) JPH08505628A (fr)
CN (1) CN1114961A (fr)
CA (1) CA2153228A1 (fr)
SG (1) SG52262A1 (fr)
WO (1) WO1994015958A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU682857B2 (en) * 1993-03-29 1997-10-23 Du Pont Pharmaceuticals Company Novel processes and intermediate compounds for the preparation of platelet clycoprotein IIb/IIIa inhibitors
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US7001921B1 (en) 1995-01-23 2006-02-21 Biogen Idec Ma Inc. Cell adhesion inhibitors
US5821329A (en) * 1996-06-06 1998-10-13 Tanabe Seiyaku Co., Ltd. Cyclic peptide inhibitors of β1 and β2 integrin-mediated adhesion
WO1996040781A1 (fr) * 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
WO1997002289A1 (fr) * 1995-07-06 1997-01-23 Zeneca Limited Inhibiteurs peptidiques de la fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9613112D0 (en) 1996-06-21 1996-08-28 Zeneca Ltd Chemical compounds
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
DE69737769T2 (de) 1996-07-25 2008-05-15 Biogen Idec Ma Inc., Cambridge Molekülmodell für vla-4-inhibitoren
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
DE19647381A1 (de) 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en) 1996-11-15 1998-05-25 Hoechst Ag Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
WO1998046631A1 (fr) * 1997-04-11 1998-10-22 Eli Lilly And Company Echantillotheques combinatoires de macrocycles peptidomimetiques et procedes correspondants
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO1999025731A1 (fr) 1997-11-13 1999-05-27 Toray Industries, Inc. Peptides cycliques et leur utilisation medicinale
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ509199A (en) 1998-05-28 2003-10-31 Biogen Inc A VLA-4 inhibitor: oMePUPA-V
AU8143798A (en) * 1998-06-15 2000-01-05 Ixsys, Incorporated Peptide inhibitors of alpha v beta3 and alpha v beta5
DK1113810T3 (da) 1998-09-14 2009-04-06 Univ Texas Fremgangsmåder til behandling af multipelt myelom og myelom-induceret knogleresorption under anvendelse af antagonister af integrin/receptor-binding
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
BR0013248A (pt) 1999-08-13 2002-07-23 Biogen Inc Inibidores da adesão celular
DK2140881T3 (da) 1999-12-16 2013-05-06 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
AU2003211560A1 (en) 2002-02-20 2003-09-09 Ajinomoto Co., Inc. Novel phenylalanine derivative
US7570871B2 (en) 2002-11-12 2009-08-04 Koninklijke Philips Electronics N.V. Continue recording channel feature for personal video recorder
MXPA06003141A (es) 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
KR20110098980A (ko) 2003-12-22 2011-09-02 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
JP4682155B2 (ja) 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
CA2714335A1 (fr) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methodes de traitement de la sclerose en plaques par administration d'une alpha-foetoproteine combinee a un antagoniste de l'integrine
KR20110008086A (ko) 2008-04-11 2011-01-25 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
WO2011123652A1 (fr) 2010-04-02 2011-10-06 The Regents Of The University Of Michigan Peptides de type rf-amide et procédés les utilisant
WO2018140510A1 (fr) 2017-01-25 2018-08-02 Biogen Ma Inc. Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
CN110423265A (zh) * 2019-04-03 2019-11-08 中国药科大学 一种环肽类trf2抑制剂的制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008739A1 (fr) * 1990-11-13 1992-05-29 The Scripps Research Institute Anticorps se liant a un site de liaison induit par ligand sur l'integrine, et induisant l'activation de l'integrine
WO1992008476A1 (fr) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides inhibant la liaison plaquettaire de molecules d'ashesion
EP0537654A2 (fr) * 1991-10-18 1993-04-21 F. Hoffmann-La Roche Ag Anticorps contre l'intégrine alpha6
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
WO1993020229A1 (fr) * 1992-04-03 1993-10-14 Genentech, Inc. ANTICORPS DE L'INTEGRINE ALPHA v BETA 3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008476A1 (fr) * 1990-11-07 1992-05-29 The Scripps Research Institute Peptides inhibant la liaison plaquettaire de molecules d'ashesion
WO1992008739A1 (fr) * 1990-11-13 1992-05-29 The Scripps Research Institute Anticorps se liant a un site de liaison induit par ligand sur l'integrine, et induisant l'activation de l'integrine
EP0537654A2 (fr) * 1991-10-18 1993-04-21 F. Hoffmann-La Roche Ag Anticorps contre l'intégrine alpha6
WO1993020229A1 (fr) * 1992-04-03 1993-10-14 Genentech, Inc. ANTICORPS DE L'INTEGRINE ALPHA v BETA 3
US5225531A (en) * 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val

Also Published As

Publication number Publication date
CN1114961A (zh) 1996-01-17
SG52262A1 (en) 1998-09-28
WO1994015958A2 (fr) 1994-07-21
CA2153228A1 (fr) 1994-07-21
EP0677060A1 (fr) 1995-10-18
JPH08505628A (ja) 1996-06-18

Similar Documents

Publication Publication Date Title
WO1994015958A3 (fr) Inhibiteurs peptidiques de l'adhesion cellulaire
CA2314607A1 (fr) Utilisation d'activateurs de ppar-.gamma. en dermatologie
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
MX9706069A (es) Nuevos inhibidores de la trombina.
CA2078572A1 (fr) Recepteurs de l'acetylcholine de type nicotinique isoles de neurones humains et methodes d'utilisation
EP2016953A3 (fr) Antagonistes de facteur de croissance cellulaire endothéliale vasculaire et utilisations associées
MX9806064A (es) Composicion de enzimas para disociacion de tejidos.
IE45086L (en) Amino acids.
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
WO2001068586A3 (fr) INHIBITEURS D'INTEGRINES α4β1 ET α4β¿7?
WO2001038547A3 (fr) Polypeptides comprenant des multimeres de signaux de localisation nucleaire ou de domaines de transduction de proteine et utilisations de ces derniers pour transferer des molecules dans des cellules
EP1746160A3 (fr) Antagonistes du récepteur du facteur de croissance des hepatocytes et leurs utilisations
ATE214607T1 (de) Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose
AU5147598A (en) Methods for reversibly inhibiting myelopoiesis in mammalian tissue
IL142905A0 (en) Functional antagonists of hedgehog activity
AU5596298A (en) Integrin antagonists
DK1007537T3 (da) Receptor-protein med betegnelsen 2F1
WO1997031936A3 (fr) Nouveaux derives d'ortho-naphthoquinone, procede de synthese correspondant et utilisation de ces derives pour inhiber la croissance cellulaire neoplasique
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
MX9801987A (es) Nuevos derivados de aminoacido, su obtencion y su uso.
WO1999026932A8 (fr) Derives heterocycliques substitues par un groupe amidino et leur utilisation en tant qu'anticoagulants
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
LTIP610A (en) Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds
AU1031697A (en) Novel geranylgeranyl-derivatives, process for the preparation thereof and related pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2153228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994906984

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994906984

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994906984

Country of ref document: EP